Cocrystal Pharma (COCP) Accounts Payables (2010 - 2026)

Cocrystal Pharma (COCP) has 15 years of Accounts Payables data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 16.28% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 16.28% YoY), and the FY2025 full-year result was $890000.0, down 42.28% from the prior year.
• Accounts Payables rose to $1.9 million in Q1 2026, from $890000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $3.0 million in Q4 2023 to a low of $568000.0 in Q3 2023.
• A 5-year average of $1.5 million and a median of $1.4 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 242.31% in 2023 and plunged 57.98% in 2024, its largest moves.
• Tracing COCP's Accounts Payables over 5 years: stood at $976000.0 in 2022, then soared by 209.63% to $3.0 million in 2023, then slumped by 48.97% to $1.5 million in 2024, then plunged by 42.28% to $890000.0 in 2025, then surged by 111.91% to $1.9 million in 2026.
• Business Quant data shows COCP's Accounts Payables at $1.9 million in Q1 2026, $890000.0 in Q4 2025, and $1.2 million in Q3 2025.